文献速递胸部肿瘤

卡瑞利珠单抗联合卡铂与紫杉醇一线治疗晚期鳞状非小细胞肺癌(CameL-Sq):一项3期试验

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
PubMed 文献 · J Thorac Oncol · 2021-12-16

CameL-Sq是一项在中国53个中心开展的双盲随机3期试验,389例IIIB-IV期鳞状NSCLC患者按1:1接受卡瑞利珠单抗或安慰剂联合卡铂+紫杉醇4-6周期后维持治疗。卡瑞利珠单抗组中位PFS 8.5个月 vs 安慰剂组4.9个月(p<0.0001),中位OS未达到 vs 14.5个月(p<0.0001)。两周期后ctDNA清除与更长的PFS和OS独立相关(均p<0.0001)。

要点

  • 卡瑞利珠单抗联合化疗较安慰剂联合化疗显著延长中位PFS(8.5 vs 4.9个月,p<0.0001)和中位OS(未达到 vs 14.5个月,p<0.0001)。
  • 两组均未观察到意外的治疗相关免疫不良事件。
  • 卡瑞利珠单抗联合化疗组中,两周期治疗后ctDNA清除独立关联更长的PFS和OS(均p<0.0001)。

核心结论

  • 研究结果支持卡瑞利珠单抗联合化疗作为晚期鳞状NSCLC的一线治疗选择。
  • 治疗中ctDNA动态变化具有预测卡瑞利珠单抗联合化疗疗效的潜力。

研究设计与样本

  • CameL-Sq为双盲、随机3期试验(NCT03668496),在中国53个中心开展。
  • 共389例IIIB-IV期鳞状NSCLC患者按1:1随机接受4-6周期卡铂+紫杉醇联合卡瑞利珠单抗或安慰剂(每3周),随后卡瑞利珠单抗或安慰剂维持治疗。
  • 193例分配至卡瑞利珠单抗联合化疗组、196例分配至安慰剂联合化疗组纳入疗效和安全性分析。
  • 在基线和两周期治疗后采集外周血ctDNA样本。

主要发现

  • 卡瑞利珠单抗联合化疗组较安慰剂联合化疗组显著延长中位PFS(8.5 vs 4.9个月,p<0.0001)。
  • 卡瑞利珠单抗联合化疗组中位OS未达到,安慰剂联合化疗组为14.5个月(p<0.0001)。
  • 两组均未观察到意外的治疗相关免疫不良事件。
  • 卡瑞利珠单抗联合化疗组中,两周期治疗后ctDNA清除独立关联显著更长的PFS(p<0.0001)和OS(p<0.0001)。

临床怎么用

  • 作者认为研究结果支持卡瑞利珠单抗联合化疗作为晚期鳞状NSCLC的一线治疗选择。
  • 作者认为治疗中ctDNA动态变化具有预测卡瑞利珠单抗联合化疗疗效的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody against programmed cell death protein 1, has exhibited antitumor activity and tolerability across various tumors, including lung cancers. We conducted this double-blind, randomized phase 3 trial to investigate the efficacy and safety of camrelizumab or placebo plus chemotherapy as first-line treatment for patients with advanced squamous NSCLC. The predictive value of circulating tumor DNA (ctDNA) dynamics was also analyzed. METHODS: CameL-sq, a double-blind, randomized phase 3 trial (NCT03668496), was conducted in 53 centers in the People's Republic of China. A total of 389 patients with stage IIIB-IV squamous NSCLC were randomized (1:1) to receive 4 to 6 cycles of carboplatin plus paclitaxel with camrelizumab or placebo (every 3 wk), followed by maintenance therapy with camrelizumab or placebo. Peripheral blood ctDNA samples were collected at baseline and the time after two cycles of treatment. RESULTS: Of 389 eligible patients, 193 patients allocated camrelizumab plus chemotherapy and 196 patients allocated placebo plus chemotherapy were included in the efficacy and safety analysis. The results revealed significantly prolonged progression-free survival (median, 8.5 vs. 4.9 mo; p <0.0001) and overall survival (median, not reached vs. 14.5 mo; p <0.0001) with camrelizumab-chemotherapy versus placebo-chemotherapy. No unexpected treatment immune-related adverse events were observed in both groups. Biomarker analysis revealed that ctDNA clearance after two cycles of treatment was independently associated with dramatically longer progression-free survival (p <0.0001) and overall survival (p <0.0001) in camrelizumab plus chemotherapy group. CONCLUSIONS: Our findings support camrelizumab plus chemotherapy as a first-line treatment option in advanced squamous NSCLC. On-treatment ctDNA dynamics exhibited the potency to predict the efficacy of camrelizumab plus chemotherapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ren S, Chen J, Xu X, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2021. PMID: 34923163. doi:10.1016/j.jtho.2021.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。